U.S. court upholds patents on Pfizer's cancer drug

Reuters
The Pfizer logo is seen at their world headquarters in New York April 28, 2014. REUTERS/Andrew Kelly

(Reuters) - A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said. Pfizer filed the lawsuit in June 2010 after Mylan attempted to market a generic version of Sutent, patented until 2021. Sutent, which is approved for use in advanced kidney cancer, gastrointestinal and pancreatic tumors, raked in sales of about $578 million in the first half of this year. The case is Pfizer Inc v. Mylan Pharmaceuticals Inc, U.S. District Court, District of Delaware, No. 10-cv-00528-GMS. (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)